Key result
Transcatheter MViV can incorporate residual iatrogenic ASDs for access to treat degenerated surgical bioprostheses.
Why the study?
Degenerated surgical mitral bioprostheses may require reintervention, and residual iatrogenic ASDs can complicate hemodynamics but may also be incorporated into a transcatheter MViV procedural strategy.
Case Report (n=1)
A residual iatrogenic ASD can be successfully utilized for transseptal access during mitral valve-in-valve procedures and closed simultaneously.
May be considered for transseptal access in MViV with favorable residual iASD anatomy; extends procedural options but remains hypothesis-generating.
BACKGROUND: Degenerated surgical mitral bioprostheses may require reintervention, and transcatheter mitral valve-in-valve implantation has emerged as a less invasive alternative. Residual iatrogenic atrial septal defects (ASDs) may complicate hemodynamics, but they can also be incorporated into the procedural strategy. CASE SUMMARY: . A 27-mm balloon-expandable valve was implanted, followed by ASD closure using a 32-mm occluder. The procedure improved valve hemodynamics and reduced central venous pressure from 26.5 to 9.4 mm Hg, with marked symptomatic improvement. TAKE-HOME MESSAGE: A residual iatrogenic ASD can be used for mitral valve-in-valve access and closed in the same procedure in selected patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a case report in Degenerated surgical mitral bioprosthesis (n=1). Transcatheter mitral valve-in-valve implantation and ASD closure was evaluated on Valve hemodynamics and central venous pressure. Transcatheter mitral valve-in-valve implantation via a residual iatrogenic ASD reduced central venous pressure from 26.5 to 9.4 mm Hg with marked symptomatic improvement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: